TITLE

Antiretrovirals

PUB. DATE
May 2008
SOURCE
Reactions Weekly;5/10/2008, Issue 1201, p8
SOURCE TYPE
Periodical
DOC. TYPE
Case Study
ABSTRACT
The article describes the case of eighteen patients in the ASCENT study or EPIC study with HIV infection developed hepatotoxicity during treatment with antiretrovirals. Patients in the ASCENT study were receiving aplaviroc, zidovudine and lamivudine twice daily and those in the EPIC study were receiving aplaviroc, lopinavir and ritonavir twice daily.
ACCESSION #
32684411

 

Related Articles

  • An early START: major study finds early HIV treatment is best. Whittaker, Bill // HIV Australia;Jul2015, Vol. 13 Issue 2, p4 

    The article discusses the START randomised controlled clinical study of HIV treatment. Topics discussed include an antiretroviral called zidovudine (AZT) which became available in Australia in the late 1980s, relation between antiretroviral treatment and CD4+ cell counts of HIV patients, and a...

  • Predictors of Virological Outcome and Safety in Primary HIV Type 1—Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005. Hoen, Bruno; Cooper, David A.; Lampe, Fiona C.; Perrin, Luc; Clumeck, Nathan; Phillips, Andrew N.; Goh, Li-Ean; Lindback, Stefan; Sereni, Daniel; Gazzard, Brian; Montaner, Julio; Stellbrink, Hans-Jurgen; Lazzarin, Adriano; Ponscarme, Diane; Staszewski, Shlomo; Mathiesen, Lars; Smith, Don; Finlayson, Robert; Weber, Rainer; Wegmann, Laurence // Clinical Infectious Diseases;8/1/2007, Vol. 45 Issue 3, p381 

    Background. Initiation of antiretroviral therapy during primary human immunodeficiency virus (HIV)-1 infection may confer long-term benefit. Methods. After initiation of zidovudine, lamivudine, abacavir, and amprenavir therapy in patients in the QUEST cohort, predictors of virological outcome,...

  • Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection. Cooper, David A.; Heera, Jayvant; Goodrich, James; Tawadrous, Margaret; Saag, Michael; DeJesus, Edwin; Clumeck, Nathan; Walmsley, Sharon; Ting, Naitee; Coakley, Eoin; Reeves, Jacqueline D.; Reyes-Teran, Gustavo; Westby, Mike; Van Der Ryst, Elna; Ive, Prudence; Mohapi, Lerato; Mingrone, Horacio; Horban, Andrzej; Hackman, Frances; Sullivan, John // Journal of Infectious Diseases;3/15/2010, Vol. 201 Issue 6, p803 

    Background. The MERIT (Maraviroc versus Efavirenz in Treatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in antiretroviral-naive patients with R5 human immunodeficiency virus type 1 (HIV-1) infection. Methods. Patients screened for R5 HIV-1 were...

  • Prevalence of Transmitted Drug Resistance and Impact of Transmitted Resistance on Treatment Success in the German HIV-1 Seroconverter Cohort. Bartmeyer, Barbara; Kuecherer, Claudia; Houareau, Claudia; Werning, Johanna; Keeren, Kathrin; Somogyi, Sybille; Kollan, Christian; Jessen, Heiko; Dupke, Stephan; Hamouda, Osamah // PLoS ONE;2010, Vol. 5 Issue 10, p1 

    Background: The aim of this study is to analyse the prevalence of transmitted drug resistance, TDR, and the impact of TDR on treatment success in the German HIV-1 Seroconverter Cohort. Methods: Genotypic resistance analysis was performed in treatment-naïve study patients whose sample was...

  • Delayed Progression to Death and to AIDS in a Hong Kong Cohort of Patients with Advanced HIV Type 1 Disease During the Era of Highly Active Antiretroviral Therapy. Ka Hing Wong; Kenny Chi Wai Chan; Shui Shan Lee // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p853 

    Background. The magnitude of the impact of highly active antiretroviral therapy (HAART) since its introduction in non-Western countries is not entirely clear. We studied disease progression among adult patients with advanced human immunodeficiency virus type 1 (HIV-1) infection in the pre-HAART...

  • Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study. Panos, George; Samonis, George; Alexiou, Vangelis G.; Kavarnou, Garyfallia A.; Charatsis, Gerasimos; Falagas, Matthew E. // Current HIV Research;May2008, Vol. 6 Issue 3, p257 

    HAART has substantially decreased mortality and morbidity among HIV-infected patients. We retrospectively analyzed morbidity and mortality in a cohort of HIV-infected adult patients with prolonged and frequent follow up (1987-2006). The study was divided in pre-HAART and HAART period for...

  • Modelling T4 cell count as a marker of HIV progression in the absence of any defense mechanism. Yadavalli, Venkata S. Sarma; Labeodan, Moremi Morire OreOluwapo; Udayabaskaran, Swaminathan; Forche, N. // Orion;2010, Vol. 26 Issue 2, p113 

    The T4 cell count, which is considered one of the markers of disease progression in an HIV infected individual, is modelled in this paper. The World Health Organisation has recently advocated that countries encourage HIV infected individuals to commence antiretroviral treatments once their T4...

  • HIV-Induced T-Cell Activation/Exhaustion in Rectal Mucosa Is Controlled Only Partially by Antiretroviral Treatment. Rueda, Cesar Mauricio; Velilla, Paula Andrea; Chougnet, Claire A.; Montoya, Carlos Julio; Rugeles, Maria Teresa // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Peripheral blood T-cells from untreated HIV-1-infected patients exhibit reduced immune responses, usually associated with a hyperactivated/exhausted phenotype compared to HAART treated patients. However, it is not clear whether HAART ameliorates this altered phenotype of T-cells in the...

  • Antiretroviral prescribing delayed among certain patients.  // PharmacoEconomics & Outcomes News;4/24/2004, Issue 451, p7 

    Discusses a study conducted by researchers in the U.S. in April 2004, which revealed the delay of antiretroviral therapy for nonadherent HIV-infected patients caused by physicians who follow guidelines on antiretroviral treatment. Number of patients with HIV infections that were evaluated;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics